Cited by 553Neuroscience and Neuropharmacology ResearchGenetics and Neurodevelopmental DisordersProtein Kinase Regulation and GTPase Signaling

CASK: a novel dlg/PSD95 homolog with an N-terminal calmodulin-dependent protein kinase domain identified by interaction with neurexins

Open access
Hata, Y, Butz, S, Sudhof, TC·1996·The Journal of Neuroscience

Abstract

Neurexins are neuronal cell surface proteins with hundreds of isoforms. In yeast two-hybrid screens for intracellular molecules interacting with different neurexins, we identified a single interacting protein called CASK. CASK is composed of an N-terminal Ca2+, calmodulin- dependent protein kinase sequence and a C-terminal region that is similar to the intercellular junction proteins dlg-A, PSD95/SAP90, SAP97, Z01, and Z02 and that contains DHR-, SH3-, and guanylate kinase domains. CASK is enriched in brain in synaptic plasma membranes but is also detectable at low levels in all tissues tested. The cytoplasmic domains of all three neurexins bind CASK in a salt-labile interaction. In neurexin I, this interaction is dependent on the C-terminal three residues. Thus, CASK is a membrane-associated protein that combines domains found in Ca2+ - activated protein kinases and in proteins specific for intercellular junctions, suggesting that it may be a signaling molecule operating at the plasma membrane, possibly in conjunction with neurexins.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.16-08-02488.1996

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The CASK PDZ-domain tightly binds to the C terminus of neurexins, constituting the first example of a "type II" PDZ-domain interaction.

    “CASK was discovered because its PDZ-domain—a component of the MAGUK domains—tightly binds to the C terminus of neurexins, thereby constituting the first example of a “type II” PDZ-domain interaction (Hata et al., 1996).”

    From The Presynaptic Active Zone (2012) · cites this paper as Hata et al., 1996

    The Abstract (page unavailable) reports that CASK was identified through its interaction with neurexins and that binding to neurexin I depends on its C-terminal three residues. The Properties and tissue distribution section (page unavailable) says the interaction is salt-labile and suggests it is weak; it does not establish binding by the PDZ domain specifically or call this the first type II PDZ-domain interaction. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • CASK is composed of an N-terminal CaM kinase-like domain that constitutes a catalytically active, unusual protein kinase, and a C-terminal set of domains characteristic of MAGUKs.

    “CASK is composed of an N-terminal CaM kinase-like domain that constitutes a catalytically active, unusual protein kinase (Mukherjee et al., 2008), and a C-terminal set of domains characteristic of MAGUKs (for membrane-associated guanylate kinases; Hata et al., 1996).”

    From The Presynaptic Active Zone (2012) · cites this paper as Hata et al., 1996

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hata, Y., Butz, S., & Sudhof, T.
Affiliations
The University of Texas Southwestern Medical Center (US)
Venue
The Journal of Neuroscience
Published
1996-04-15
Volume
16
Issue
8
Pages
2488-2494
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1919311176
Cited by
553
References
1
Citations by year
2026: 13 · 2025: 7 · 2024: 6 · 2023: 19 · 2022: 21 · 2021: 19 · 2020: 15 · 2019: 13 · 2018: 11 · 2017: 13 · 2016: 15 · 2015: 15 · 2014: 20 · 2013: 17 · 2012: 15
FWCI
10.56
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (R01 MH52804, R01MH052804)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
CASK, neurexin, calcium/calmodulin-dependent protein kinase, PSD-95, synaptic plasma membrane, SH3 domain, guanylate kinase domain, protein-protein interaction, brain, signaling molecules
MeSH terms
Animals, Base Sequence, Brain, Cloning, Molecular, Molecular Sequence Data, Protein Kinases, Calcium-Calmodulin-Dependent Protein Kinases, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review